The healthcare giant reported a consolidated net profit of Rs 433 crore for Q1FY26, marking a significant 42% increase compared to Rs 305 crore in the same period last year. Sequentially, profit after tax (PAT) rose 11% from Rs 390 crore recorded in Q4FY25.
Revenue from operations grew 15% year-on-year to Rs 5,842 crore in Q1FY26, up from Rs 5,086 crore in Q1FY25. On a sequential basis, the topline improved 4.5% compared to Rs 5,592 crore in Q4FY25.
Segment-wise revenue performance:
Healthcare services revenue came in at Rs 2,974 crore in Q1FY26, rising from Rs 2,843 crore in the previous quarter (Q4FY25) and Rs 2,654 crore in the same quarter last year (Q1FY25).
Retail health & diagnostics revenue reached Rs 435 crore in Q1FY26, up from Rs 394 crore in Q4FY25 and Rs 366 crore in Q1FY25.
Digital health & pharmacy distribution revenue stood at Rs 2,472 crore in Q1FY26, compared to Rs 2,376 crore in the previous quarter and Rs 2,082 crore in the year-ago period.
The positive earnings and steady revenue growth across all business segments have boosted investor confidence, driving the stock price upward.
Technical Outlook
The 14-day Relative Strength Index (RSI) for Apollo Hospitals Enterprise is currently at 47.5. Typically, an RSI below 30 indicates that a stock is oversold and may be undervalued, while an RSI above 70 suggests it is overbought and could be due for a correction. At 47.5, the stock is in a neutral zone, showing neither strong buying nor selling pressure.
From a moving averages perspective, Apollo Hospitals Enterprise is exhibiting a bullish trend as it is trading above all 8 key Simple Moving Averages (SMAs) — ranging from the short-term 5-day SMA to the long-term 200-day SMA. This consistent position above multiple SMAs suggests strong upward momentum and positive investor sentiment.
